Pfizer Inc (PFE)

34.26
NYSE : Health Care
Prev Close 34.06
Day Low/High 33.99 / 34.35
52 Wk Low/High 28.74 / 37.39
Avg Volume 25.94M
Exchange NYSE
Shares Outstanding 6.07B
Market Cap 206.69B
EPS 1.20
P/E Ratio 29.11
Div & Yield 1.28 (3.80%)

Latest News

Pfizer Prices $1,065,000,000 Debt Offering

Pfizer Prices $1,065,000,000 Debt Offering

Pfizer Inc. (NYSE: PFE) today announced the pricing of $1,065,000,000 aggregate principal amount of 4.

Ronald E. Blaylock Elected To Pfizer's Board Of Directors

Ronald E. Blaylock Elected To Pfizer's Board Of Directors

Pfizer Inc. today announced the election of Ronald E.

Latest Portfolio Earnings and Dividend Reminders

News and updates on seven DSA positions.

Meet 4 Women Serving on the Boards of 4 Companies at the Same Time

Meet 4 Women Serving on the Boards of 4 Companies at the Same Time

Four women serve on the boards of four S&P 500 companies at the same time.

A Pfizer Ratio Spread Opportunity

We're pursuing a call enhancement play on PFE via a ratio call spread.

Go With Allergan, Celgene and 'Big Mo'

Go With Allergan, Celgene and 'Big Mo'

These two large-cap drug giants should be core parts of any well-diversified portfolio.

World's Biggest Drugmaker Quits London and Swiss Listings

World's Biggest Drugmaker Quits London and Swiss Listings

Pfizer, the world's biggest drugmaker, said Wednesday that it's abandoning its European listings due to liquidity issues.

Four Women Match Men Sitting on the Most S&P 500 Boards

Four Women Match Men Sitting on the Most S&P 500 Boards

More than a dozen people sit on the four boards for components of the S&P 500, of which four are women.

Global Financial News: Earnings In The Spotlight

Global Financial News: Earnings In The Spotlight

A week full of financial reports continues, as Bayer and Lloyds post full-year earnings

Pfizer Quits London and Swiss Listings, Says 'Limited Liquidity' in European Trading

Pfizer Quits London and Swiss Listings, Says 'Limited Liquidity' in European Trading

Pfizer, the world's biggest drugmaker, said Wednesday that it's abandoning its European listings due to liquidity issues.

Bristol-Myers Buys Back Shares, Shuffles Board

Bristol-Myers Buys Back Shares, Shuffles Board

The drug company will carry out 80% of a $2B repurchase by Feb. 28 after pressure from insurgent Jana Partners. Icahn also reportedly acquired a stake, with focus on M&A.

Boeing, GE and Oracle CEOs Support Border Adjustment Tax in Letter to Congress

Boeing, GE and Oracle CEOs Support Border Adjustment Tax in Letter to Congress

16 executives from companies like Boeing, General Electric, Oracle and Pfizer sent a letter to congressional leaders on Tuesday supporting the House GOP tax plan.

Execs from Boeing, Pfizer Send Letter Backing House GOP Tax Plan

Execs from Boeing, Pfizer Send Letter Backing House GOP Tax Plan

Executives from 16 companies, including Boeing, Oracle and Pfizer, are weighing in to support the increasingly-contentious border adjustment tax

Pfizer Announces Acceptance Of Regulatory Submission For Inotuzumab Ozogamicin By The U.S. Food And Drug Administration

Pfizer Announces Acceptance Of Regulatory Submission For Inotuzumab Ozogamicin By The U.S. Food And Drug Administration

Pfizer Inc. (NYSE:PFE) today announced that a Biologics License Application (BLA) for inotuzumab ozogamicin has been accepted for filing and granted Priority Review by the U.

Clovis, Tesaro Soar on Astrazeneca Phase Three News

Clovis, Tesaro Soar on Astrazeneca Phase Three News

AstraZeneca shares, meanwhile, were less-than-moved by the news.

Stock Investors May Be Rooting for a Trump Overseas Tax Holiday, But Bondholders Should Be Wary

Stock Investors May Be Rooting for a Trump Overseas Tax Holiday, But Bondholders Should Be Wary

Companies like Apple, Microsoft and Cisco can afford aggressive buybacks and dividends, but activists could force others with offshore cash to choose between equity and debt holders.

New Data In Crohn's Disease Patients Shows Similar Efficacy And Safety Profiles For INFLECTRA® And REMICADE®a

New Data In Crohn's Disease Patients Shows Similar Efficacy And Safety Profiles For INFLECTRA® And REMICADE®a

Data announced jointly today by Pfizer Inc. (NYSE:PFE) and Celltrion Healthcare, at the 12 th Congress of the European Crohn's and Colitis Organisation (ECCO), showed that for patients with moderate-to-severe Crohn's...

Here Comes Pfizer's Powerful Breakout

Here Comes Pfizer's Powerful Breakout

The charts say so.

Pfizer Announces Top-Line Results From The Oral Strategy Trial Of XELJANZ® (tofacitinib Citrate) Compared To Humira® (adalimumab)

Pfizer Announces Top-Line Results From The Oral Strategy Trial Of XELJANZ® (tofacitinib Citrate) Compared To Humira® (adalimumab)

Pfizer Inc. (NYSE:PFE) announced today top-line results from ORAL Strategy, a Phase 3B/4 study of XELJANZ ® (tofacitinib citrate) 5mg twice daily (BID) in the treatment of moderate to severe rheumatoid arthritis (RA).

Stocks with a heart

Stocks with a heart

Here are three stock picks with a romantic spin

5 Ways Allergan Can Keep Up Momentum

5 Ways Allergan Can Keep Up Momentum

Allergan's most-recent quarterly financial report for Q4/2016 showed solid results.

Grading Our Portfolio Moves

How did we do with our recommendations?

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Eli Lilly Is Great Stock to Buy Now

Eli Lilly Is Great Stock to Buy Now

Here's why the pharmaceutical company is a solid addition to your portfolio.

How I'd Play Our Current Portfolio (Part IV)

Here's my take and suggested actions for Owens-Illinois, Pfizer and PPL.

Here's How the Tom Price Stock Portfolio Is Performing Now That He Is Confirmed

Here's How the Tom Price Stock Portfolio Is Performing Now That He Is Confirmed

Tom Price will now head the Department of Health and Human Services.

Portfolio Update: AbbVie, Pfizer and Sonoco Report Earnings; and Don't Miss These Must-Own Dates!

An update of earnings, payout dates and upcoming dividend reminders.

Cramer: Here's the Reason for Allergan's Remarkable Run

Cramer: Here's the Reason for Allergan's Remarkable Run

Static doesn't work in this industry. Pipelines work.

TheStreet Quant Rating: B- (Buy)